Living donor liver transplantation for end-stage liver disease
- VernacularTitle:活体肝移植治疗终末期肝病
- Author:
Xuehao WANG
;
Feng ZHANG
;
Xiangcheng LI
;
Lianbao KONG
;
Beicheng SUN
;
Guoqiang LI
;
Feng CHENG
;
Ling Lü
- Publication Type:Journal Article
- Keywords:
Liver transplantation;
Living donor;
End-stage liver disease;
Wilson disease
- From:
Chinese Journal of Digestive Surgery
2008;7(2):89-91
- CountryChina
- Language:Chinese
-
Abstract:
objective To investigate preoperative donor and recipient assessment,choice of surgical options in living donor liver transplantation(LDLT).Methods The clinical data of 95 patients who underwent LDLT from January 1995 to October 2007 in our center were retrospectively analyzed.Of all,92 recipients were benign end-stage liver disease patients (including 45 patients with Wilson disease),and 3 were malignant hepatic carcinbma patients.Results Thirty-one fight lobes without middle hepatic vein(MHV),3 right lobes with MHV,51 left lobes with MHV.and 10 left lobes or left lateral lobes without MHV were obtained.All the donors recovered after operation. Recipients with benign end-stage liver disease were followed up for 1 to 86 months,and the 1-,3-,5-year accumulative survival rates were 89%(82 cases),78%(71 cases)and 73%(67 cases),respectively. The 1-,3-,5-year survival rates of patients with Wilson disease were 92%(42 cases),89%(40 cases)and 76%(34 cases),respectively. For the 3 patients with malignant hepatic carcinoma,2 died and 1 was alive and well. The copper metabolism was back to normal in both donors and recipients. Conclusions Establishment of a system for the safety of donors is basic for LDLT. The key to raise the recipients' survival rates is to choose the optimal surgical approach. LDLT is effective in treating Wilson disease.
